Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 420,000 | $20.90 | $8,778,000.00 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,560,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionCommon Stock | 483,559 | $18.90 | $9,139,265.10 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,140,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:59 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 43,520 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004489 · doc4.xml · derivative · entry 6 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,520 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:59 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 13,886 | $35.98 | $499,618.28 |
DisclosureSEC source: 0001225208-18-004489 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,633 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:59 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 12,214 | $36.26 | $442,879.64 |
DisclosureSEC source: 0001225208-18-004489 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,519 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:59 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionCommon Stock | 43,520 | $18.90 | $822,528.00 |
DisclosureSEC source: 0001225208-18-004489 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2018 Filed Feb 28, 2018 00:32 UTC |
Dolsten MikaelPresident R&D
|
OtherPhantom Stock Units · Derivative | 16,547 | $36.26 | $599,994.22 |
DisclosureSEC source: 0001225208-18-004457 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,093 Underlying: Common Stock · 16,547 shares Expires not disclosed F6 · derivative.exercise_price: Each unit represents one phantom share of common stock. F7 · derivative.exercise_date: The units, held under the Deferred Compensation Plan are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F7 · derivative.expiration_date: The units, held under the Deferred Compensation Plan are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:43 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 18,119 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003963 · doc4.xml · derivative · entry 4 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,119 Underlying: Common Stock · 18,119 shares Expires 2025-02-22 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:43 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 21,673 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003963 · doc4.xml · derivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,673 Underlying: Common Stock · 21,673 shares Expires 2023-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:43 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 4,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-003963 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,481 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:47 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 120,792 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003965 · doc4.xml · derivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,792 Underlying: Common Stock · 120,792 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:47 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 144,485 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003965 · doc4.xml · derivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,485 Underlying: Common Stock · 144,485 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:45 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
GrantStock Appreciation Rights · Derivative | 226,485 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003964 · doc4.xml · derivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,485 Underlying: Common Stock · 226,485 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:45 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
GrantStock Appreciation Rights · Derivative | 270,910 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003964 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,910 Underlying: Common Stock · 270,910 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:47 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 120,792 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003966 · doc4.xml · derivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,792 Underlying: Common Stock · 120,792 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:47 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 144,485 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003966 · doc4.xml · derivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,485 Underlying: Common Stock · 144,485 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:47 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 75,495 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003967 · doc4.xml · derivative · entry 2 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,495 Underlying: Common Stock · 75,495 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:47 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 90,303 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003967 · doc4.xml · derivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,303 Underlying: Common Stock · 90,303 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 45,297 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003968 · doc4.xml · derivative · entry 2 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,297 Underlying: Common Stock · 45,297 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
Hwang AngelaGroup President
|
GrantStock Appreciation Rights · Derivative | 54,182 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003968 · doc4.xml · derivative · entry 1 Hwang Angela · CIK 0001725474 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,182 Underlying: Common Stock · 54,182 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 25,064 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003969 · doc4.xml · derivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,064 Underlying: Common Stock · 25,064 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 29,981 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003969 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,981 Underlying: Common Stock · 29,981 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 40,767 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003970 · doc4.xml · derivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,767 Underlying: Common Stock · 40,767 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 48,764 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003970 · doc4.xml · derivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,764 Underlying: Common Stock · 48,764 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 81,535 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003971 · doc4.xml · derivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,535 Underlying: Common Stock · 81,535 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 97,528 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003971 · doc4.xml · derivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,528 Underlying: Common Stock · 97,528 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 54,356 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003972 · doc4.xml · derivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,356 Underlying: Common Stock · 54,356 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
Lewis-Hall Freda CExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 65,018 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003972 · doc4.xml · derivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,018 Underlying: Common Stock · 65,018 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 33,218 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003973 · doc4.xml · derivative · entry 2 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,218 Underlying: Common Stock · 33,218 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:50 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 39,733 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003973 · doc4.xml · derivative · entry 1 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,733 Underlying: Common Stock · 39,733 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 25,064 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003978 · doc4.xml · derivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,064 Underlying: Common Stock · 25,064 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
OLSON LAURIE JExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 29,981 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003978 · doc4.xml · derivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,981 Underlying: Common Stock · 29,981 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 392,574 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003979 · doc4.xml · derivative · entry 2 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 392,574 Underlying: Common Stock · 392,574 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 469,577 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003979 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,577 Underlying: Common Stock · 469,577 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 120,792 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003980 · doc4.xml · derivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,792 Underlying: Common Stock · 120,792 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
YOUNG JOHN DGroup President
|
GrantStock Appreciation Rights · Derivative | 144,485 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003980 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,485 Underlying: Common Stock · 144,485 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 60,396 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003981 · doc4.xml · derivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,396 Underlying: Common Stock · 60,396 shares Expires 2025-02-22 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 20:54 UTC |
SUSMAN SALLYExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 72,243 | $0.00 Strike: $35.74 | $0.00 |
DisclosureSEC source: 0001225208-18-003981 · doc4.xml · derivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,243 Underlying: Common Stock · 72,243 shares Expires 2023-02-22 F1 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F1 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 01:58 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 676 | $36.01 | $24,342.76 |
DisclosureSEC source: 0001225208-18-003655 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,763 Underlying: Common Stock · 676 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 20:15 UTC |
BOURLA ALBERTChief Operating Officer
|
GrantPhantom Stock Units SSP · Derivative | 36 | $36.56 | $1,316.16 |
DisclosureSEC source: 0001225208-18-000964 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,048 Underlying: Common Stock · 36 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 20:15 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 18 | $36.56 | $658.08 |
DisclosureSEC source: 0001225208-18-000965 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,342 Underlying: Common Stock · 18 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 20:15 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 36 | $36.56 | $1,316.16 |
DisclosureSEC source: 0001225208-18-000966 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,002 Underlying: Common Stock · 36 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:51 UTC |
Echevarria JosephDirector
|
GrantPhantom Stock Units · Derivative | 949.06 | $36.22 | $34,374.95 |
DisclosureSEC source: 0001225208-18-000095 · doc4.xml · derivative · entry 1 Echevarria Joseph · CIK 0001633137 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,785.867 Underlying: Common Stock · 949.06 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:51 UTC |
KILTS JAMES MDirector
|
GrantPhantom Stock Units · Derivative | 1,025.19 | $36.22 | $37,132.38 |
DisclosureSEC source: 0001225208-18-000096 · doc4.xml · derivative · entry 1 KILTS JAMES M · CIK 0001025094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,204.801 Underlying: Common Stock · 1,025.19 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:51 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 949.06 | $36.22 | $34,374.95 |
DisclosureSEC source: 0001225208-18-000097 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,703.849 Underlying: Common Stock · 949.06 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:51 UTC |
SANGER STEPHEN WDirector
|
GrantPhantom Stock Units · Derivative | 1,121.62 | $36.22 | $40,625.08 |
DisclosureSEC source: 0001225208-18-000098 · doc4.xml · derivative · entry 1 SANGER STEPHEN W · CIK 0001204994 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,246.372 Underlying: Common Stock · 1,121.62 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:51 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 1,121.62 | $36.22 | $40,625.08 |
DisclosureSEC source: 0001225208-18-000099 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,641.079 Underlying: Common Stock · 1,121.62 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:51 UTC |
BOURLA ALBERTChief Operating Officer
|
GrantPhantom Stock Units SSP · Derivative | 20 | $36.22 | $724.40 |
DisclosureSEC source: 0001225208-18-000100 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,012 Underlying: Common Stock · 20 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 29, 2017 Filed Jan 2, 2018 23:51 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $36.22 | $144.88 |
DisclosureSEC source: 0001225208-18-000101 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,324 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 22:39 UTC |
READ IAN CDirector · Chairman & CEO
|
GrantStock Appreciation Rights · Derivative | 1,372,213 | $0.00 Strike: $36.22 | $0.00 |
DisclosureSEC source: 0001225208-18-000424 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372,213 Underlying: Common Stock · 1,372,213 shares Expires 2022-12-29 F1 · derivative.exercise_date: The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through March 31, 2019 (or such earlier time as determined by the Board of Directors) and he is either employed by Pfizer or is subject to. and complies with a non-compete and non-solicitation agreement until March 31, 2021 and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022). F1 · derivative.expiration_date: The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through March 31, 2019 (or such earlier time as determined by the Board of Directors) and he is either employed by Pfizer or is subject to. and complies with a non-compete and non-solicitation agreement until March 31, 2021 and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.